Rekvina Laboratories Ltd
Rekvina Laboratories Ltd (VINRKLB) last reported results for the quarter ended Jun 2026, with sales of ₹0.67 crore and net profit of ₹-0.12 crore. The stock last traded at ₹50.5, a market capitalisation of ₹56.1 crore. Over the past 52 weeks the stock has ranged between ₹6.75 and ₹59.4. Figures are as of 6 Oct 2026 and are not real time.
Rekvina Laboratories Ltd share price and key metrics
- Current price
- ₹50.5
- Market cap
- ₹56.1 cr
- Book value
- ₹-1.02
- ROE
- %
- ROCE
- -333%
- Dividend yield
- 0.00%
- 52w high / low
- 59.4/6.75
Metrics as of 6 Oct 2026. Not real time.
Track Rekvina Laboratories Ltd
Cruxal reads every Rekvina Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Rekvina Laboratories Ltd growth and returns
- 10 Years
- 36%
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -94%
- 10 Years
- 25%
- 5 Years
- 63%
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Rekvina Laboratories Ltd quarterly results
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0.2 | 0.35 | 0.72 | 0.67 |
| Expenses | 0.07 | 0.02 | 0.04 | 0.04 | 0.23 | 0.47 | 0.78 | 0.79 |
| Operating profit | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| OPM % | — | — | — | — | -15.00% | -34.29% | -8.33% | -17.91% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| EPS (₹) | -0.06 | -0.02 | -0.03 | -0.03 | -0.02 | -0.10 | -0.05 | -0.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Rekvina Laboratories Ltd annual results
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0 | 0 | 0 | 0 | -0.04 | 0 | 0 | 0 | 1.27 | 1.94 |
| Operating profit | -0.06 | -0.05 | -0.1 | -0.15 | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| OPM % | -100.00% | — | — | — | — | — | — | — | — | -19.69% | -17.01% |
| Net profit | -0.06 | -0.02 | -0.08 | 0 | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| EPS (₹) | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.21 | -0.27 |
TTM is the trailing twelve months to the most recent quarter.
Rekvina Laboratories Ltd balance sheet
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.21 | -3.35 | -4.24 |
| Borrowings | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.25 | 1.47 |
| Other liabilities | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.17 | 0.12 | 0.94 |
| Total liabilities | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.18 |
| Fixed assets | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
| Other assets | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.01 | 0.03 | 1.18 |
| Total assets | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.18 |
As reported by the company. Total assets equal total liabilities by construction.
Rekvina Laboratories Ltd cash flow
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| Cash from investing | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.21 | 0.58 |
| Net cash flow | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.02 | -0.01 |
| Free cash flow | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| CFO / operating profit | 67% | -20% | 20% | 7% | 17% | 50% | — | 50% | 136% | 236% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Rekvina Laboratories Ltd operating ratios
| Per year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | -11.11% | -3.45% | -12.70% | -50.00% | -160.00% | 0.00% | -333.33% |
| Debtor days | 1,703.33 | — | — | — | 0.00 | — | 172.44 |
| Inventory days | — | — | — | — | 0.00 | — | 0.00 |
| Cash conversion cycle | 1,703.33 | — | — | — | 0.00 | — | 172.44 |
| Working capital days | 1,460.00 | — | — | — | -1,642.50 | — | -359.25 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Rekvina Laboratories Ltd shareholding pattern
Promoters held 77.00% at Aug 2026, up from 41.30% at Sep 2025.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 77.00% |
| Public | 58.70% | 58.70% | 58.71% | 58.72% | 58.72% | 58.72% | 58.70% | 23.00% |
| No. of shareholders | 2,430 | 2,427 | 2,442 | 2,427 | 504 | 2,475 | 2,465 | 2,457 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Rekvina Laboratories Ltd corporate filings
- Rekvina Laboratories appoints Mr. Subrata Samanta as CFO effective 07-10-2026Company Updatemedium impact
Cruxal's analysis: Rekvina Laboratories Limited has announced the appointment of Mr. Subrata Samanta as…
Read the full analysis - Rekvina Laboratories Limited conducts multiple shareholder resolutions with full approval, indicating stable governance and shareholder supportAGM/EGMlow impact
Cruxal's analysis: Rekvina Laboratories Limited has held its AGM on 29th September 2026, with resolutions…
Read the full analysis - Summary of Proceeding of Annual General MeetingAGM/EGMmedium impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- Rekvina Laboratories Limited Announces Resignation of Managing Director and Change of Registered OfficeCompany Updatemedium impact
Cruxal's analysis: Rekvina Laboratories Limited has formally notified the resignation of Mr. Amit Shah from…
Read the full analysis - Rekvina Laboratories Ltd announces change in registered office address effective September 23, 2026Company Updatelow impact
Cruxal's analysis: Rekvina Laboratories Ltd has formally notified the exchange regarding a change in its…
Read the full analysis - Rekvina Laboratories Limited Announces Resignation of Managing Director Amit Mukesh ShahCompany Updatemedium impact
Cruxal's analysis: Rekvina Laboratories Limited has formally notified the BSE of the resignation of Mr. Amit…
Read the full analysis - Rekvina Laboratories Ltd releases Annual Report for FY2025-26Otherslow impact
Cruxal's analysis: Rekvina Laboratories has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Rekvina Laboratories Limited announces 38th AGM, board appointments, and resignation of Company SecretaryAGM/EGMlow impact
Cruxal's analysis: Rekvina Laboratories Limited has scheduled its 38th Annual General Meeting for September…
Read the full analysis - Rekvina Laboratories Limited announces resignation of Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Rekvina Laboratories Limited has formally notified the exchange regarding the resignation…
Read the full analysis - Rekvina Laboratories Limited: Promoters Increase Stake to 60.30% via Open Offer and Preferential AllotmentInsider Trading / SASThigh impact
Cruxal's analysis: Rekvina Laboratories Limited has undergone a significant change in shareholding…
Read the full analysis - Dhruvalkumar Patel acquires 10.01% stake in Rekvina Laboratories Limited via open offer and preferential allotmentInsider Trading / SASThigh impact
Cruxal's analysis: Dhruvalkumar Patel has acquired 11,12,562 equity shares of Rekvina Laboratories Limited…
Read the full analysis - Rekvina Laboratories Ltd issues clarification on recent stock price movementCompany Updatelow impact
Cruxal's analysis: Rekvina Laboratories Ltd has issued a formal clarification regarding the recent movement…
Read the full analysis - Rekvina Laboratories reports widening net loss of 12.05 lakh for Q1 FY27 amid rising operational costsBoard Meetingmedium impact
Cruxal's analysis: Rekvina Laboratories Limited reported a net loss of 12.05 lakh for the quarter ended 30…
Read the full analysis - Rekvina Laboratories to acquire Radiant Parenterals for 4.63 crore via share swap and raises 46 lakh via cash preferential issueCompany Updatehigh impact
Cruxal's analysis: Rekvina Laboratories Limited has completed the acquisition of 100% equity in Radiant…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.